Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT04171661
Active, not recruiting Phase EARLY_PHASE1

Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa

NCT04171661 · tracked via the Priya Life Science Canada tracker
Sponsor
CHU de Quebec-Universite Laval
Phase
Phase EARLY_PHASE1
Started
2019-12-10
Last updated
2026-03-19

Condition(s) studied

Epidermolysis Bullosa Dystrophica

Investigational drug(s) / intervention(s)

SASS →

SASS: SASS applied on chronic skin wounds as skin graft

Study summary

Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting chronic open wounds that are not responding to dressings, topical preparations (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The Self-Assembled Skin Substitutes will be used to cover wounds.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
This clinical trial was custom designed for one patient

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Hospital for Sick Children Toronto Ontario

More CHU de Quebec-Universite Laval trials in Canada

Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes Recruiting
Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial Active, not recruiting
Personalized PRRT of Neuroendocrine Tumors Active, not recruiting
Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life Active, not recruiting
SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04171661 on ClinicalTrials.gov ↗ ← All trials in Canada